118 related articles for article (PubMed ID: 8584685)
1. Effects of subchronic treatments with SM-9018, a novel 5-HT2 and D2 antagonist, on dopamine and 5-HT receptors in rats.
Ohno Y; Ishibashi T; Okada K; Ishida K; Nakamura M
Prog Neuropsychopharmacol Biol Psychiatry; 1995 Oct; 19(6):1091-101. PubMed ID: 8584685
[TBL] [Abstract][Full Text] [Related]
2. Effects of perospirone (SM-9018), a potential atypical neuroleptic, on dopamine D1 receptor-mediated vacuous chewing movement in rats: a role of 5-HT2 receptor blocking activity.
Ohno Y; Ishida-Tokuda K; Ishibashi T; Nakamura M
Pharmacol Biochem Behav; 1997 Aug; 57(4):889-95. PubMed ID: 9259021
[TBL] [Abstract][Full Text] [Related]
3. Effects of SM-9018, a novel 5-HT2 and D2 receptor antagonist, on electrically-evoked [3H]acetylcholine release from rat striatal slices.
Ishida K; Ohno Y; Ishibashi T; Nakamura M
Gen Pharmacol; 1996 Oct; 27(7):1203-7. PubMed ID: 8981068
[TBL] [Abstract][Full Text] [Related]
4. Contrasting effects of SM-9018, a potential atypical antipsychotic, and haloperidol on c-fos mRNA expression in the rat striatum.
Ishibashi T; Ikeda K; Ishida K; Yasui J; Tojima R; Nakamura M; Ohno Y
Eur J Pharmacol; 1996 May; 303(3):247-51. PubMed ID: 8813576
[TBL] [Abstract][Full Text] [Related]
5. Potential role of 5-HT2 and D2 receptor interaction in the atypical antipsychotic action of the novel succimide derivative, perospirone.
Ohno Y; Ishida-Tokuda K; Ishibashi T; Sakamoto H; Tagashira R; Horisawa T; Yabuuti K; Matsumoto K; Kawabe A; Nakamura M
Pol J Pharmacol; 1997 Aug; 49(4):213-9. PubMed ID: 9437764
[TBL] [Abstract][Full Text] [Related]
6. Cyclic benzamides as mixed dopamine D2/serotonin 5-HT2 receptor antagonists: potential atypical antipsychotic agents.
Norman MH; Rigdon GC; Navas F; Cooper BR
J Med Chem; 1994 Aug; 37(16):2552-63. PubMed ID: 7914539
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of bradykinesia induction by SM-9018, a novel 5-HT2 and D2 receptor antagonist, using the mouse pole test.
Ohno Y; Ishida K; Ikeda K; Ishibashi T; Okada K; Nakamura M
Pharmacol Biochem Behav; 1994 Sep; 49(1):19-23. PubMed ID: 7816873
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of perospirone (SM-9018), a novel serotonin-2 and dopamine-2 receptor antagonist, and other antipsychotics in the conditioned fear stress-induced freezing behavior model in rats.
Ishida-Tokuda K; Ohno Y; Sakamoto H; Ishibashi T; Wakabayashi J; Tojima R; Morita T; Nakamura M
Jpn J Pharmacol; 1996 Oct; 72(2):119-26. PubMed ID: 8912913
[TBL] [Abstract][Full Text] [Related]
9. Effects of chronic treatments with SM-9018, a potential atypical neuroleptic, on behavioral dopaminergic and serotonergic sensitivities in rats.
Ohno Y; Ishida K; Ishibashi T; Ikeda K; Kato T; Nakamura M
Gen Pharmacol; 1995 May; 26(3):489-94. PubMed ID: 7789721
[TBL] [Abstract][Full Text] [Related]
10. Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system.
Andersson JL; Nomikos GG; Marcus M; Hertel P; Mathé JM; Svensson TH
Naunyn Schmiedebergs Arch Pharmacol; 1995 Oct; 352(4):374-85. PubMed ID: 8532065
[TBL] [Abstract][Full Text] [Related]
11. Effects of perospirone, a novel 5-HT2 and D2 receptor antagonist, on Fos protein expression in the rat forebrain.
Ishibashi T; Tagashira R; Nakamura M; Noguchi H; Ohno Y
Pharmacol Biochem Behav; 1999 Aug; 63(4):535-41. PubMed ID: 10462181
[TBL] [Abstract][Full Text] [Related]
12. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats.
Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Kumagai T; Nakazato A; Nagamine M; Yamaguchi K; Tomisawa K
Br J Pharmacol; 1997 Jun; 121(3):515-25. PubMed ID: 9179395
[TBL] [Abstract][Full Text] [Related]
13. Serotonergic involvement in haloperidol-induced catalepsy.
Neal-Beliveau BS; Joyce JN; Lucki I
J Pharmacol Exp Ther; 1993 Apr; 265(1):207-17. PubMed ID: 8386235
[TBL] [Abstract][Full Text] [Related]
14. Persistent spontaneous oral dyskinesias in haloperidol-withdrawn rats neonatally lesioned with 6-hydroxydopamine: absence of an association with the Bmax for [3H]raclopride binding to neostriatal homogenates.
Huang NY; Kostrzewa RM; Li C; Perry KW; Fuller RW
J Pharmacol Exp Ther; 1997 Jan; 280(1):268-76. PubMed ID: 8996206
[TBL] [Abstract][Full Text] [Related]
15. In vivo occupation of dopamine D1, D2 and serotonin2A receptors by novel antipsychotic drug, SM-9018 and its metabolite, in rat brain.
Takahashi Y; Kusumi I; Ishikane T; Koyama T
J Neural Transm (Vienna); 1998; 105(2-3):181-91. PubMed ID: 9660096
[TBL] [Abstract][Full Text] [Related]
16. Effects of chronic neuroleptic treatments on dopamine D1 and D2 receptors: homogenate binding and autoradiographic studies.
Huang N; Ase AR; Hébert C; van Gelder NM; Reader TA
Neurochem Int; 1997 Mar; 30(3):277-90. PubMed ID: 9041559
[TBL] [Abstract][Full Text] [Related]
17. Molecular and behavioral effects mediated by Gs-coupled adenosine A2a, but not serotonin 5-Ht4 or 5-Ht6 receptors following antipsychotic administration.
Ward RP; Dorsa DM
Neuroscience; 1999 Mar; 89(3):927-38. PubMed ID: 10199625
[TBL] [Abstract][Full Text] [Related]
18. Antagonism at 5-HT(2A) receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats.
Wadenberg MG; Browning JL; Young KA; Hicks PB
Pharmacol Biochem Behav; 2001 Mar; 68(3):363-70. PubMed ID: 11325387
[TBL] [Abstract][Full Text] [Related]
19. Differential regulation of dopamine receptors after chronic typical and atypical antipsychotic drug treatment.
Tarazi FI; Florijn WJ; Creese I
Neuroscience; 1997 Jun; 78(4):985-96. PubMed ID: 9174067
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological profile of MS-377, a novel antipsychotic agent with selective affinity for sigma receptors.
Takahashi S; Sonehara K; Takagi K; Miwa T; Horikomi K; Mita N; Nagase H; Iizuka K; Sakai K
Psychopharmacology (Berl); 1999 Aug; 145(3):295-302. PubMed ID: 10494578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
